It has been reported that targeted HER2 (human epidermal growth factor receptor 2) and VEGFR2 (vascular endothelial growth factor receptor 2) inhibitor drugs could prolong the survival of some GC patients6,7. This evidence concerns the gene KDR and gastric cancer.